EXACT Therapeutics

Equities

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-25 am EDT			5-day change	1st Jan Change
6.8 ^NOK	0.00%		-2.86%	-43.33%

Apr. 19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

EXACT Therapeutics AS Appoints Hilary Mcelwaine-Johnn as Chief Medical Officer

January 25, 2021 at 08:00 pm EST

EXACT Therapeutics AS announced the appointment of Dr. Hilary McElwaine-Johnn as Chief Medical Officer. Dr. McElwaine-Johnn will be based at the newly opened London office of EXACT-Tx at the Translation & Innovation Hub (i-Hub) at White City.

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	23-10-31	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	23-09-27	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	23-09-26	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	23-09-25	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	23-09-06	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	23-09-05	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	23-08-07	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	23-08-06	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	23-07-31	CI
EXACT Therapeutics AS Announces Management Changes	23-06-09	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	23-03-27	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	23-02-02	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	23-02-02	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22-12-22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22-12-22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22-11-22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-21	CI
EXACT Therapeutics Appoints Chief Medical Officer	22-09-16	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	22-09-15	CI
Norway's Exact Therapeutics Appoints New CFO	22-08-31	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	22-08-30	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	22-06-23	MT

Chart EXACT Therapeutics

Duration

Period

More charts

Company Profile

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-43.33%	20.42M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research